You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201351 - 201360 of 204455 results
  1. A Bioactive Nanofibrous Sewing Cuff for Treatment of Cardiac Valvular Disease

    SBC: BIOSURFACES INC            Topic: NHLBI

    PROJECT SUMMARY Cardiac valve repair or replacement is indicated when progression of degenerative disease or bacterial infection of the native valve results in valvular dysfunction, thereby impacting cardiac output. Both procedures require the use of a woven or knitted polyester material with an internal reinforcement (Teflon, silicone or metal) to either stabilize the native valve (annuloplasty r ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an Angiogenic T Cell Assay for Personalized Cytomics in Cardiovasc

    SBC: CYTOVAS, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): The goal of this research is to develop a new flow cytometry-based test for the clinical measurement of proangiogenic T cells. Such an assay does not exist today. Proangiogenic T cells, including angiogenic T cell (Tang) and Th17 subsets, participate in reparative mechanisms in the vasculature, in oncogenic angiogenesis and in other processes central to the ove ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Novel Therapeutic Approach to Hypercholesterolemia Using Next-Generation DNA Sequ

    SBC: ABEOME CORPORATION            Topic: NHLBI

    DESCRIPTION (provided by applicant): We have developed and completed a proof-of-principle on a new transgenic mouse model for comprehensive characterization of the antibody repertoire made in response to ovalbumin injection using surface antibody capture and next-generation DNA sequencing technologies. A more commercially valuable proof is now sought using a novel screening method with an emerging ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Copper Nanoparticle Impregnated, Nitric Oxide Generating Hollow Fibers for Artifi

    SBC: MEDARRAY INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): More than 190,000 people suffer from acute respiratory distress syndrome (ARDS) in the US each year, with mortality rates from 25-40% with the best treatment. In addition, there are over 12 million patients with chronic lung disease. These patients typically have 1-3 acute exacerbations of their disease state per year that cause additional short term respirat ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Wireless Vagal Nerve Stimulation System for Treating Atrial Fibrillation

    SBC: ROSELLINI SCIENTIFIC, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Atrial fibrillation (AF) is the most common cardiac arrhythmia, and is associated with substantial risk of morbidity and mortality. AF currently affects more than 2.5 million Americans and the affected population is steadily growing with our aging society. AF independently increases the risk of stroke by 4- to 5-fold, is an independent risk factor for stroke re ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Intracellular targeting Hsp70 for myocardial cytoprotection after an infarction

    SBC: RUBICON BIOTECHNOLOGY LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Heart disease statistics compiled by the American Heart Association in 2010 estimate 785,000 Americans, each year, will have a new coronary attack, another 470,000 will have a recurrent heart attack, and 195,000 will have a silent infarction, resulting in a coronary event every 25 seconds in the US. Myocardial cells affected by the infarction must endure hypoxi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Time-relevant Blood Sample Collection Using HemaSpot

    SBC: SPOT ON SCIENCES, LLC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Time-relevant Blood Sample Collection Using HemaSpot Collection of blood samples at relevant time points is critical for chronobiology (circadian rhythm) research and for predicting, diagnosing and treating chronic diseases such as diabetes, kidney and cardiovascular disease. Recent studies demonstrate that survival of at-risk patients is increased up to 5-fol ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Human Anti-WISP1 Antibodies for Treatment of Idiopathic Pulmonary Fbrosis

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): New anti-fibrotic drugs are needed to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, chronically debilitating clinical syndrome with unknown etiology and a terminal outcome. IPF symptoms include persistent cough, progressive severe shortness of breath and decreased exercise capacity. Up to 200,000 Americans suffer from this disease with expect ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy

    SBC: VANGUARD THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a poorly treated debilitating condition for which we are developing a promising, new oral prophylactic therapy. A dire need exists for our drug, as millions of patients whohave inherited SCD world-wide, ~100,000 in the US, continue to suffer with episodic pain, disability, and premature death. Hydrox ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Myocardial blood flow quantitation with the novel F-18 Flurpiridaz PET imaging tr

    SBC: SYNTERMED INCORPORATED            Topic: NHLBI

    Coronary artery disease continues to be a major contributor to the cause of death in the United States. The ability to diagnosis CAD in patients at an early stage has improved over the years resulting in reducing the mortality rate. In nuclear medicine/cardiology, the SPECT and PET myocardial perfusion imaging (MPI) methods and radiopharmaceuticals used clinically over the past 10 years have offer ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government